Search
Research
Participation in population-based case-control studies: Does the observed decline vary by socio-economic status?An Australian study of childhood leukaemia (Aus-ALL) previously reported that control participation was positively associated with socio-economic status...
News & Events
Brain Cancer Awareness Month Q&A: Dr Hetal Dholaria’s vital work for WA KidsEach year in Australia, around 120 children are diagnosed with brain cancer, the leading cause of cancer-related death in young people.
News & Events
Pioneering paediatric oncologist receives top cancer research awardAssociate Professor Rishi Kotecha, Co-Head of Leukaemia Translational Research at The Kids Research Institute Australia Cancer Centre and Consultant Paediatric Oncologist at Perth Children's Hospital, has been named Cancer Council WA’s 2024 Cancer Researcher of the Year.
Research
MelanomaMelanoma, also known as malignant melanoma, occurs when abnormal skin cells multiply rapidly in an uncontrolled way.
Research
Brain TumourBrain tumours are the second most common cancer in children (after leukaemia).
Research
Psychosocial Outcomes in Parents of Children with Acute Lymphoblastic Leukaemia in Australia and New Zealand Through and Beyond TreatmentParents of children with acute lymphoblastic leukaemia (ALL) experience emotional distress throughout their child's treatment course. This study describes the psychological experience of Australian and New Zealand parents of children diagnosed with ALL.
Research
Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179OLIG2-expressing tumor stem cells have been shown to drive recurrence in Sonic Hedgehog (SHH)-subgroup medulloblastoma (MB) and patients urgently need specific therapies to target this tumor cell population.
Research
Propofol, Anesthesia, and Neurocognitive Outcomes in Patients with Pediatric Leukemia: Are We Missing the Forest for the Trees?Britta Regli-von Ungern-Sternberg AM FAHMS MD, PhD, DEAA, FANZA Chair of Paediatric anaesthesia, University of Western Australia; Consultant
Research
Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockadeAntibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4, programmed cell death protein/ligand 1 are approved for treatment of multiple cancer types.